State of New Jersey Common Pension Fund D grew its position in Organon & Co. (NYSE:OGN - Free Report) by 59.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 221,461 shares of the company's stock after buying an additional 82,239 shares during the period. State of New Jersey Common Pension Fund D owned 0.09% of Organon & Co. worth $3,193,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. New York State Teachers Retirement System raised its stake in shares of Organon & Co. by 20.1% during the fourth quarter. New York State Teachers Retirement System now owns 348,226 shares of the company's stock worth $5,021,000 after buying an additional 58,321 shares during the last quarter. State of Alaska Department of Revenue raised its position in shares of Organon & Co. by 417.8% during the 4th quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company's stock valued at $2,267,000 after acquiring an additional 126,882 shares during the last quarter. KLCM Advisors Inc. lifted its stake in shares of Organon & Co. by 60.4% in the 4th quarter. KLCM Advisors Inc. now owns 999,099 shares of the company's stock valued at $14,407,000 after purchasing an additional 376,055 shares during the period. UBS Group AG lifted its stake in shares of Organon & Co. by 88.3% in the 3rd quarter. UBS Group AG now owns 657,912 shares of the company's stock valued at $11,421,000 after purchasing an additional 308,470 shares during the period. Finally, Nordea Investment Management AB boosted its position in shares of Organon & Co. by 2,016.0% in the 4th quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company's stock worth $44,648,000 after purchasing an additional 2,980,945 shares during the last quarter. Institutional investors own 77.43% of the company's stock.
Insider Activity at Organon & Co.
In other news, insider Kirke Weaver purchased 2,720 shares of the company's stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $18.36 per share, with a total value of $49,939.20. Following the completion of the transaction, the insider now owns 15,181 shares of the company's stock, valued at approximately $278,723.16. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.17% of the stock is owned by company insiders.
Organon & Co. Trading Up 0.7 %
Shares of Organon & Co. stock traded up $0.13 during trading hours on Friday, reaching $18.55. 2,049,767 shares of the company's stock were exchanged, compared to its average volume of 1,996,842. The stock has a market cap of $4.74 billion, a P/E ratio of 4.64, a P/E/G ratio of 0.88 and a beta of 0.83. The company has a 50 day moving average of $18.14 and a two-hundred day moving average of $15.68. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.79.
Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.14. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. As a group, analysts expect that Organon & Co. will post 4.08 earnings per share for the current fiscal year.
Organon & Co. Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 6.04%. The ex-dividend date was Friday, February 23rd. Organon & Co.'s payout ratio is presently 28.00%.
Wall Street Analyst Weigh In
Separately, The Goldman Sachs Group raised their price target on Organon & Co. from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 20th.
Check Out Our Latest Analysis on OGN
About Organon & Co.
(
Free Report)
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Recommended Stories
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
